Review




Structured Review

Philips Healthcare t philips ingenia mri scanner
T Philips Ingenia Mri Scanner, supplied by Philips Healthcare, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mri/pmc13276324-117-6-7?v=Philips+Healthcare
Average 86 stars, based on 1 article reviews
t philips ingenia mri scanner - by Bioz Stars, 2026-06
86/100 stars

Images



Similar Products

86
Siemens Healthineers t whole body mri system
T Whole Body Mri System, supplied by Siemens Healthineers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mri/pmc13200137-153-8-13?v=Siemens+Healthineers
Average 86 stars, based on 1 article reviews
t whole body mri system - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Philips Healthcare t philips ingenia mri scanner
T Philips Ingenia Mri Scanner, supplied by Philips Healthcare, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mri/pmc13276324-117-6-7?v=Philips+Healthcare
Average 86 stars, based on 1 article reviews
t philips ingenia mri scanner - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Philips Healthcare t mri scanner
Representative axial (A-C) and sagittal (C) FLAIR images from three patients at fraction 0 (F0), fraction 15 (F15), fraction 30 (F30), and 1 month post-radiotherapy (PM1; diagnostic <t>MRI),</t> demonstrating patient-specific changes <t>in</t> <t>T2/FLAIR</t> region-of-interest (ROI) volume (V), percentage change in V relative to F0 (V rel ), and migration distance (d migrate ). The baseline ROI at F0 is outlined in pink; ROIs at F15, F30, and PM1 are outlined in dark blue. (A) Unmethylated tumor following gross total resection (GTR), without early progression, showing decreasing ROI volume with low d migrate across timepoints. (B) Unmethylated tumor following subtotal resection (STR), with early progression, showing increasing ROI volume with increasing d migrate across timepoints. (C) Methylated tumor following STR, without early progression, showing decreasing ROI volume with large d migrate across timepoints. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
T Mri Scanner, supplied by Philips Healthcare, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mri/pmc13276516-99-11-14?v=Philips+Healthcare
Average 86 stars, based on 1 article reviews
t mri scanner - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Siemens Healthineers mri scanner details
Representative axial (A-C) and sagittal (C) FLAIR images from three patients at fraction 0 (F0), fraction 15 (F15), fraction 30 (F30), and 1 month post-radiotherapy (PM1; diagnostic <t>MRI),</t> demonstrating patient-specific changes <t>in</t> <t>T2/FLAIR</t> region-of-interest (ROI) volume (V), percentage change in V relative to F0 (V rel ), and migration distance (d migrate ). The baseline ROI at F0 is outlined in pink; ROIs at F15, F30, and PM1 are outlined in dark blue. (A) Unmethylated tumor following gross total resection (GTR), without early progression, showing decreasing ROI volume with low d migrate across timepoints. (B) Unmethylated tumor following subtotal resection (STR), with early progression, showing increasing ROI volume with increasing d migrate across timepoints. (C) Methylated tumor following STR, without early progression, showing decreasing ROI volume with large d migrate across timepoints. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Mri Scanner Details, supplied by Siemens Healthineers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mri/pmc13196352-31-0-11?v=Siemens+Healthineers
Average 86 stars, based on 1 article reviews
mri scanner details - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Philips Healthcare mri images
Representative axial (A-C) and sagittal (C) FLAIR images from three patients at fraction 0 (F0), fraction 15 (F15), fraction 30 (F30), and 1 month post-radiotherapy (PM1; diagnostic <t>MRI),</t> demonstrating patient-specific changes <t>in</t> <t>T2/FLAIR</t> region-of-interest (ROI) volume (V), percentage change in V relative to F0 (V rel ), and migration distance (d migrate ). The baseline ROI at F0 is outlined in pink; ROIs at F15, F30, and PM1 are outlined in dark blue. (A) Unmethylated tumor following gross total resection (GTR), without early progression, showing decreasing ROI volume with low d migrate across timepoints. (B) Unmethylated tumor following subtotal resection (STR), with early progression, showing increasing ROI volume with increasing d migrate across timepoints. (C) Methylated tumor following STR, without early progression, showing decreasing ROI volume with large d migrate across timepoints. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Mri Images, supplied by Philips Healthcare, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mri/pmc13264218-71-12-16?v=Philips+Healthcare
Average 86 stars, based on 1 article reviews
mri images - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Siemens Healthineers 3 0 t magnetic resonance imaging mri
Representative axial (A-C) and sagittal (C) FLAIR images from three patients at fraction 0 (F0), fraction 15 (F15), fraction 30 (F30), and 1 month post-radiotherapy (PM1; diagnostic <t>MRI),</t> demonstrating patient-specific changes <t>in</t> <t>T2/FLAIR</t> region-of-interest (ROI) volume (V), percentage change in V relative to F0 (V rel ), and migration distance (d migrate ). The baseline ROI at F0 is outlined in pink; ROIs at F15, F30, and PM1 are outlined in dark blue. (A) Unmethylated tumor following gross total resection (GTR), without early progression, showing decreasing ROI volume with low d migrate across timepoints. (B) Unmethylated tumor following subtotal resection (STR), with early progression, showing increasing ROI volume with increasing d migrate across timepoints. (C) Methylated tumor following STR, without early progression, showing decreasing ROI volume with large d migrate across timepoints. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
3 0 T Magnetic Resonance Imaging Mri, supplied by Siemens Healthineers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mri/pmc13266175-41-23-29?v=Siemens+Healthineers
Average 86 stars, based on 1 article reviews
3 0 t magnetic resonance imaging mri - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Siemens Healthineers mri
Representative axial (A-C) and sagittal (C) FLAIR images from three patients at fraction 0 (F0), fraction 15 (F15), fraction 30 (F30), and 1 month post-radiotherapy (PM1; diagnostic <t>MRI),</t> demonstrating patient-specific changes <t>in</t> <t>T2/FLAIR</t> region-of-interest (ROI) volume (V), percentage change in V relative to F0 (V rel ), and migration distance (d migrate ). The baseline ROI at F0 is outlined in pink; ROIs at F15, F30, and PM1 are outlined in dark blue. (A) Unmethylated tumor following gross total resection (GTR), without early progression, showing decreasing ROI volume with low d migrate across timepoints. (B) Unmethylated tumor following subtotal resection (STR), with early progression, showing increasing ROI volume with increasing d migrate across timepoints. (C) Methylated tumor following STR, without early progression, showing decreasing ROI volume with large d migrate across timepoints. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Mri, supplied by Siemens Healthineers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mri/pmc08633812-25-7-8?v=Siemens+Healthineers
Average 86 stars, based on 1 article reviews
mri - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Philips Healthcare 3t mri scanner
Representative axial (A-C) and sagittal (C) FLAIR images from three patients at fraction 0 (F0), fraction 15 (F15), fraction 30 (F30), and 1 month post-radiotherapy (PM1; diagnostic <t>MRI),</t> demonstrating patient-specific changes <t>in</t> <t>T2/FLAIR</t> region-of-interest (ROI) volume (V), percentage change in V relative to F0 (V rel ), and migration distance (d migrate ). The baseline ROI at F0 is outlined in pink; ROIs at F15, F30, and PM1 are outlined in dark blue. (A) Unmethylated tumor following gross total resection (GTR), without early progression, showing decreasing ROI volume with low d migrate across timepoints. (B) Unmethylated tumor following subtotal resection (STR), with early progression, showing increasing ROI volume with increasing d migrate across timepoints. (C) Methylated tumor following STR, without early progression, showing decreasing ROI volume with large d migrate across timepoints. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
3t Mri Scanner, supplied by Philips Healthcare, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mri/pmc08896806-488-19-23?v=Philips+Healthcare
Average 86 stars, based on 1 article reviews
3t mri scanner - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Waisman Biomanufacturing mris
Representative axial (A-C) and sagittal (C) FLAIR images from three patients at fraction 0 (F0), fraction 15 (F15), fraction 30 (F30), and 1 month post-radiotherapy (PM1; diagnostic <t>MRI),</t> demonstrating patient-specific changes <t>in</t> <t>T2/FLAIR</t> region-of-interest (ROI) volume (V), percentage change in V relative to F0 (V rel ), and migration distance (d migrate ). The baseline ROI at F0 is outlined in pink; ROIs at F15, F30, and PM1 are outlined in dark blue. (A) Unmethylated tumor following gross total resection (GTR), without early progression, showing decreasing ROI volume with low d migrate across timepoints. (B) Unmethylated tumor following subtotal resection (STR), with early progression, showing increasing ROI volume with increasing d migrate across timepoints. (C) Methylated tumor following STR, without early progression, showing decreasing ROI volume with large d migrate across timepoints. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Mris, supplied by Waisman Biomanufacturing, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mri/pm42321586-39-1-6?v=Waisman+Biomanufacturing
Average 86 stars, based on 1 article reviews
mris - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Beijing Tiantan Biological lowfrequency fluctuation resting state functional mri
Representative axial (A-C) and sagittal (C) FLAIR images from three patients at fraction 0 (F0), fraction 15 (F15), fraction 30 (F30), and 1 month post-radiotherapy (PM1; diagnostic <t>MRI),</t> demonstrating patient-specific changes <t>in</t> <t>T2/FLAIR</t> region-of-interest (ROI) volume (V), percentage change in V relative to F0 (V rel ), and migration distance (d migrate ). The baseline ROI at F0 is outlined in pink; ROIs at F15, F30, and PM1 are outlined in dark blue. (A) Unmethylated tumor following gross total resection (GTR), without early progression, showing decreasing ROI volume with low d migrate across timepoints. (B) Unmethylated tumor following subtotal resection (STR), with early progression, showing increasing ROI volume with increasing d migrate across timepoints. (C) Methylated tumor following STR, without early progression, showing decreasing ROI volume with large d migrate across timepoints. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Lowfrequency Fluctuation Resting State Functional Mri, supplied by Beijing Tiantan Biological, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mri/pm42319649-15-43-10?v=Beijing+Tiantan+Biological
Average 86 stars, based on 1 article reviews
lowfrequency fluctuation resting state functional mri - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

Image Search Results


Representative axial (A-C) and sagittal (C) FLAIR images from three patients at fraction 0 (F0), fraction 15 (F15), fraction 30 (F30), and 1 month post-radiotherapy (PM1; diagnostic MRI), demonstrating patient-specific changes in T2/FLAIR region-of-interest (ROI) volume (V), percentage change in V relative to F0 (V rel ), and migration distance (d migrate ). The baseline ROI at F0 is outlined in pink; ROIs at F15, F30, and PM1 are outlined in dark blue. (A) Unmethylated tumor following gross total resection (GTR), without early progression, showing decreasing ROI volume with low d migrate across timepoints. (B) Unmethylated tumor following subtotal resection (STR), with early progression, showing increasing ROI volume with increasing d migrate across timepoints. (C) Methylated tumor following STR, without early progression, showing decreasing ROI volume with large d migrate across timepoints. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Journal: Clinical and Translational Radiation Oncology

Article Title: Monitoring glioblastoma dynamics during chemoradiation on the 1.5 T magnetic resonance imaging-linear accelerator

doi: 10.1016/j.ctro.2026.101200

Figure Lengend Snippet: Representative axial (A-C) and sagittal (C) FLAIR images from three patients at fraction 0 (F0), fraction 15 (F15), fraction 30 (F30), and 1 month post-radiotherapy (PM1; diagnostic MRI), demonstrating patient-specific changes in T2/FLAIR region-of-interest (ROI) volume (V), percentage change in V relative to F0 (V rel ), and migration distance (d migrate ). The baseline ROI at F0 is outlined in pink; ROIs at F15, F30, and PM1 are outlined in dark blue. (A) Unmethylated tumor following gross total resection (GTR), without early progression, showing decreasing ROI volume with low d migrate across timepoints. (B) Unmethylated tumor following subtotal resection (STR), with early progression, showing increasing ROI volume with increasing d migrate across timepoints. (C) Methylated tumor following STR, without early progression, showing decreasing ROI volume with large d migrate across timepoints. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Article Snippet: For radiotherapy planning, all patients underwent MR simulation on a 1.5 T MRI scanner (Philips Ingenia) with gadolinium-enhanced T1-weighted, T2-weighted, diffusion-weight imaging (DWI), and fluid-attenuated inversion recovery (FLAIR) volumetric sequences.

Techniques: Diagnostic Assay, Migration, Methylation

Longitudinal relative change in MR-Linac T2/FLAIR region of interest (ROI) volume from baseline (V rel , %) during radiotherapy by (a) fractionation regimen, (b) early progression status (progression ≤ 6 months after radiotherapy), (c) methylation status, and (d) combined early progression and methylation status. Dotted lines represent individual patients; solid lines indicate group medians. PM1 denotes the post-treatment MRI performed one month after radiotherapy and is shown separately for the 15-fraction and 30-fraction cohorts; patients treated with 15 fractions do not contribute data beyond F15.

Journal: Clinical and Translational Radiation Oncology

Article Title: Monitoring glioblastoma dynamics during chemoradiation on the 1.5 T magnetic resonance imaging-linear accelerator

doi: 10.1016/j.ctro.2026.101200

Figure Lengend Snippet: Longitudinal relative change in MR-Linac T2/FLAIR region of interest (ROI) volume from baseline (V rel , %) during radiotherapy by (a) fractionation regimen, (b) early progression status (progression ≤ 6 months after radiotherapy), (c) methylation status, and (d) combined early progression and methylation status. Dotted lines represent individual patients; solid lines indicate group medians. PM1 denotes the post-treatment MRI performed one month after radiotherapy and is shown separately for the 15-fraction and 30-fraction cohorts; patients treated with 15 fractions do not contribute data beyond F15.

Article Snippet: For radiotherapy planning, all patients underwent MR simulation on a 1.5 T MRI scanner (Philips Ingenia) with gadolinium-enhanced T1-weighted, T2-weighted, diffusion-weight imaging (DWI), and fluid-attenuated inversion recovery (FLAIR) volumetric sequences.

Techniques: Fractionation, Methylation

Longitudinal migration distance (d migrate , mm) of MR-Linac T2/FLAIR region of interest (ROI) during radiotherapy by (a) fractionation regimen, (b) early progression status (progression ≤ 6 months after radiotherapy), (c) methylation status, and (d) combined early progression and methylation status. Dotted lines show individual patients; solid lines indicate group medians. PM1 denotes the post-treatment MRI performed one month after radiotherapy and is shown separately for the 15-fraction and 30-fraction cohorts; patients treated with 15 fractions do not contribute data beyond F15.

Journal: Clinical and Translational Radiation Oncology

Article Title: Monitoring glioblastoma dynamics during chemoradiation on the 1.5 T magnetic resonance imaging-linear accelerator

doi: 10.1016/j.ctro.2026.101200

Figure Lengend Snippet: Longitudinal migration distance (d migrate , mm) of MR-Linac T2/FLAIR region of interest (ROI) during radiotherapy by (a) fractionation regimen, (b) early progression status (progression ≤ 6 months after radiotherapy), (c) methylation status, and (d) combined early progression and methylation status. Dotted lines show individual patients; solid lines indicate group medians. PM1 denotes the post-treatment MRI performed one month after radiotherapy and is shown separately for the 15-fraction and 30-fraction cohorts; patients treated with 15 fractions do not contribute data beyond F15.

Article Snippet: For radiotherapy planning, all patients underwent MR simulation on a 1.5 T MRI scanner (Philips Ingenia) with gadolinium-enhanced T1-weighted, T2-weighted, diffusion-weight imaging (DWI), and fluid-attenuated inversion recovery (FLAIR) volumetric sequences.

Techniques: Migration, Fractionation, Methylation